A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate. (Q47973517)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 February 2011

Language	Label	Description	Also known as
English	A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate.	scientific article published on 22 February 2011

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

0 references

malaria vaccine

1 reference

based on heuristic

inferred from title

Christopher B Fox

8

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

13

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Michael Theisen

object named as

Michael Theisen

15

0 references

14

object named as

Steven G Reed

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

author name string

Susana Lousada-Dietrich

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Prajakta S Jogdand

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Søren Jepsen

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Vera V Pinto

4

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Sisse B Ditlev

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Michael Christiansen

6

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Severin Olesen Larsen

7

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Vanitha S Raman

9

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Randall F Howard

10

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Thomas S Vedvick

11

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

Gregory Ireton

12

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

language of work or name

0 references

publication date

22 February 2011

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

29

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

17

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

3284-3292

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Naturally acquired antibodies to the glutamate-rich protein are associated with protection against plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Humoral responses to plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich pro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

B cell memory and the long-lived plasma cell

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Maintenance of serological memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Competence and competition: the challenge of becoming a long-lived plasma cell

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

The IgG Fc receptor family

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

In vivo veritas : lessons from immunoglobulin transfer experiments in malaria patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Protection against a malaria challenge by sporozoite inoculation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

based on heuristic

inferred from DOI database lookup

Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood-stage antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.022

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2011.02.022

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/21349366

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47973517&oldid=1775329220"